Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Phase 1/2 Not yet recruiting 25 enrolled Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of fruquintinib and pirfenidone in combination with anti-PD-1 antibody in patients with standard treatment failure of advanced or metastatic pMMR/MSS colorectal adenocarcinoma.

Timeline

Start: 2024-07-22
Primary completion: 2026-07-22
Completion: 2026-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fruquintinib	Small molecule	3 mg	Oral
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Pirfenidone	Small molecule	200 mg	Oral
Subject	Pirfenidone	Small molecule	500 mg	Oral

Indications

No indication recorded.